Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 183
News
News | 11 May 2021

Vivimed Labs to manufacture, market Favipiravir tablets

The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India

News
News | 11 May 2021

CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating

The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.

News
News | 11 May 2021

Alembic reports net profit of Rs. 71.94 Cr in Q4FY21

Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021

News
News | 10 May 2021

Remdesivir allocation made upto 16th May: Gowda

State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals

News
News | 10 May 2021

Jubilant Pharma wins over Bracco's legal appeals in the US Court of Appeals

Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office

News
News | 10 May 2021

Cipla signs agreement with Lilly to expand access to COVID-19 treatment in India

Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)

News
News | 10 May 2021

Sun Pharma signs agreement with Eli Lilly for expanding access to Baricitinib

Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19

News
News | 10 May 2021

Lupin enters into agreement with Lilly to expand access for COVID-19

Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.

News
News | 10 May 2021

Zydus Wellness reports Rs. 133.13 Cr consolidated PAT in Q4FY21

Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in-their respective categories as on March 2021.

News
News | 07 May 2021

Roche receives emergency use authorisation of COVID-19 drug

This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India

News
News | 07 May 2021

Lonza announces expansion plans for mammalian manufacturing facilities

The facility is expected to be completed in 2024

News
News | 07 May 2021

PerkinElmer to donate 1 million rapid COVID-19 antigen test kits in India

Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India

News
News | 06 May 2021

Alembic announces USFDA approval for two drugs

Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5% has an estimated market size of US $80 million for twelve months ending December 2020 according to IQVIA

News
News | 06 May 2021

Govt. allocates 16.5 lakh vials of Remdesivir between May 3-9

Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago

News
News | 05 May 2021

Morepen Laboratories net profit up 189%

R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices

News
News | 05 May 2021

Natco receives emergency use approval for Baricitinib tablets

The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic

News
News | 04 May 2021

Govt. gives order for 16 cr COVID-19 vaccine doses

As of 2nd May 2021, the Government has provided more 16.54 crore COVID-19 vaccine doses to States/UTs free of cost

News
News | 04 May 2021

Glenmark launches Ryaltris-AZ at affordable price

First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg

News
News | 03 May 2021

RPG Life Sciences reports Rs. 6.92 crore PAT in Q4 FY2020-21

The company reported total income of Rs.390.05 crores during the 12 months period ended March 31, 2021

News
News | 03 May 2021

Ajanta Pharma Q4FY21 consolidated PAT drops QoQ to Rs. 159.26 Cr

The companyreported total income of Rs.2915.67 crores during the 12 months period ended March 31, 2021

Startup

Digitization